Friday, December 7th, 2018
The New Jersey Innovation Institute (NJII), an NJIT Corporation, hosted Food and Drug Administration (FDA), Director Center for Biologics Evaluation and Research (CEBR), Peter Marks M.D., Ph.D., at a roundtable with biopharma industry leaders in early December. Dr. Marks is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue and gene therapies. FDA colleagues joining Dr. Marks included Senior Advisor for Counterterrorism and Medical Countermeasures, Dr.